Abeona licenses REGENXBIO's NAV AAV9 vector for rare lysosomal storage diseases; Agreement Terminated/Cancelled
Abeona Therapeutics Inc. licensed REGENXBIO Inc.'s adeno-associated virus vector NAV AAV9 to develop and commercialize in vivo gene therapies for four rare inherited lysosomal storage disorders (LSDs): Sanfilippo syndrome Type A (or mucopolysaccharidosis (MPS) IIIA), Sanfilippo syndrome Type B (MPS IIIB), neuronal ceroid lipofuscinosis Type 1 (CLN1, also known as infantile Batten disease), and CLN3 (also known as juvenile Batten disease).
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.